Academic radiology · 2025
MR Imaging Features of Malignant Tenosynovial Giant Cell Tumors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dutta Anika R, Wenger Doris E, Thorpe Matthew P, Frick Matthew A, Folpe Andrew L, Broski Stephen M
Аннотация
RATIONALE AND OBJECTIVES: To examine MRI characteristics of malignant tenosynovial giant cell tumors (TSGCTs) and elucidate features to differentiate benign and malignant TSGCTs.
MATERIALS AND METHODS: With IRB approval, the medical record was retrospectively reviewed from 2004-2024 for cases of pathologically-proven benign and malignant TSGCTs evaluated by MRI.
RESULTS: 12 malignant TSGCTs (5F/7M, mean age 48.7 +/- 17.6 years) and 23 benign TSGCTs (13F/10M, mean age 43.7 +/- 18.7 years) were identified. There was no significant difference in age (p=0.45), gender (p=0.63), MRI signal characteristics (T1 signal p=0.57, T2 signal p=0.46, T2 signal heterogeneity p>0.99, presence of low T2 signal p>0.99), type of enhancement (presence of enhancement p=0.21, degree of enhancement p=0.12, heterogenous vs. homogenous enhancement p=0.21, presence of non-enhancing areas p=0.11), blooming artifact (p=0.065), or presence of perilesional edema (p=0.16) between benign and malignant TSGCTs. Four MRI features were more commonly associated with malignant TSGCTs: extra-articular location (p=0.009), irregular margins (p=0.0014), perilesional vessels (p=0.0014), and larger average maximal dimension (8.6 +/- 8.4 cm malignant vs. 2.8 +/- 2.2 cm benign, p=0.036).
CONCLUSION: Although there are overlapping MRI characteristics between benign and malignant TSGCTs, malignant TSGCTs are more likely to exhibit larger size, extra-articular location, irregular margins and prominent perilesional vessels compared to their benign counterparts. Some malignant TSGCTs may not be associated with a synovial-lined structure on imaging.
MATERIALS AND METHODS: With IRB approval, the medical record was retrospectively reviewed from 2004-2024 for cases of pathologically-proven benign and malignant TSGCTs evaluated by MRI.
RESULTS: 12 malignant TSGCTs (5F/7M, mean age 48.7 +/- 17.6 years) and 23 benign TSGCTs (13F/10M, mean age 43.7 +/- 18.7 years) were identified. There was no significant difference in age (p=0.45), gender (p=0.63), MRI signal characteristics (T1 signal p=0.57, T2 signal p=0.46, T2 signal heterogeneity p>0.99, presence of low T2 signal p>0.99), type of enhancement (presence of enhancement p=0.21, degree of enhancement p=0.12, heterogenous vs. homogenous enhancement p=0.21, presence of non-enhancing areas p=0.11), blooming artifact (p=0.065), or presence of perilesional edema (p=0.16) between benign and malignant TSGCTs. Four MRI features were more commonly associated with malignant TSGCTs: extra-articular location (p=0.009), irregular margins (p=0.0014), perilesional vessels (p=0.0014), and larger average maximal dimension (8.6 +/- 8.4 cm malignant vs. 2.8 +/- 2.2 cm benign, p=0.036).
CONCLUSION: Although there are overlapping MRI characteristics between benign and malignant TSGCTs, malignant TSGCTs are more likely to exhibit larger size, extra-articular location, irregular margins and prominent perilesional vessels compared to their benign counterparts. Some malignant TSGCTs may not be associated with a synovial-lined structure on imaging.